Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Codagenix-Serum Join Fray To Develop SARS-CoV-2 Vaccine

Executive Summary

Codagenix, a company backed by Novartis, Merck and the Bill & Melinda Gates Foundation, has tied up with India’s Serum Institute to develop a vaccine against SARS-CoV-2, joining a heated race against the dreaded COVID-19 outbreak.

You may also be interested in...



Novavax-Serum Institute Seal Win-Win Deal For COVID-19 Vaccine

Novavax has granted Serum Institute rights to develop, manufacture and commercialize its COVID-19 vaccine candidate in selected regions, in another endorsement of the Indian group's capabilities. The agreement, which expands on an earlier association, gives Serum exclusive marketing rights in India until the deal ends and non-exclusive rights for developing countries to the end of the pandemic, with the US firm getting half of net revenue.

India's Serum Joins Oxford Efforts To Expedite COVID-19 Vaccine

After partnering with Merck KGaA and Cobra Biologics, Oxford University has now tied up with Serum Institute of India to manufacture its COVID-19 vaccine and a marketing pact is likely. With clinical trials of the ChAdOx1 nCoV-19 vaccine underway, Serum intends to set aside other COVID-19 vaccine development plans for the time being.

IIL-Griffith Univ Readying Reasonably Priced COVID-19 Vaccine

The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL043097

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel